Grifols has received $21 million from the Michael J. Fox Foundation to fund a pilot study analyzing the company’s repository of longitudinal Parkinson’s disease (PD) plasma samples in hopes of developing an early-warning system for the emergence of PD.
Researchers have discovered a link between a chronic gut infection caused by cytomegalovirus and the development of Alzheimer’s disease in some people.
A study led by researchers at Stanford Medicine has shown that variation in vaccine durability can, in part, be attributed to a type of blood cell called megakaryocytes, typically implicated in blood clotting.
The Centers for Medicare and Medicaid Services released the 2026 Advance Notice for the Medicare Advantage and the Medicare Part D Prescription Drug Programs that would update payment policies for these programs.
Tryngolza (olezarsen) has been approved by the U.S. Food and Drug Administration to be used with diet to reduce triglycerides (TG) in adults with familial chylomicronemia syndrome.
Results from a recent study suggest coupling HA molecules from various flu strains could make flu vaccines more effective.
The U.S. Food and Drug Administration (FDA) has approved VIMKUNYA (chikungunya vaccine, recombinant) for injection, the first virus-like particle (VLP) single-dose chikungunya vaccine in the U.S. for persons 12 years of age and older.
GSK’s Penmenvy (meningococcal groups A, B, C, W and Y vaccine) has been approved by the U.S. Food and Drug Administration for use in individuals aged 10 through 25 years.
The Centers for Medicare and Medicaid Services (CMS) has announced the selection of 15 additional drugs covered under Medicare Part D for price negotiations.
The U.S. Food and Drug Administration has approved Vertex Pharmaceutical’s Journavx (suzetrigine), a new type of prescription pain medication for adults to treat moderate to severe acute pain.
The National Institutes of Health has awarded a $3.4 million grant to help establish a new Autoimmunity Center of Excellence at the University of California, Los Angeles.
Findings of a Phase III randomized controlled trial showed Pfizer’s RSV Prefusion F (RSVpreF) vaccine triggered strong immune responses among people aged 60 years and older during its first two seasons.
